NCT06901102Not yet recruitingPhase 1/2
Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial
Bee Venom As Immunomodulator and Its Effect on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Prospective Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 28 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate the effectiveness of bee venom injections as a treatment for chronic kidney disease (CKD)-mineral bone disorder (MBD) in patients undergoing hemodialysis. MBD is a common complication in CKD patients, leading to abnormal mineral metabolism, bone disease, and increased cardiovascular risks. Current treatments are often inadequate and can have significant side effects. In this study, we will compare the effects of bee venom injections with standard care treatments in hemodialysis patients. Bee venom is known for its potential anti-inflammatory and immunomodulatory properties, which may help improve mineral metabolism and bone health regulation in these patients. By stimulating regulatory T cells (Tregs) through bee venom, we aim to reduce inflammation and restore bone health. We hope to answer whether bee venom can effectively reduce mineral bone disorder markers (such as calcium, phosphorus, and parathyroid hormone levels) and improve bone density in hemodialysis patients. The results could lead to a new treatment option for CKD-MBD, improving patient outcomes and quality of life.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 23 Mar 2025
- Start date
- 10 Apr 2025
- Primary completion date
- 10 Oct 2025
- Lead sponsor
- Mansoura University
- Diseases
- Chronic kidney disease
- NCT number
- NCT06901102
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 60
- From 10 Apr 2025 to the primary completion date, 10 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of medications affecting bone metabolism (e.g., calcitonin, denosumab, estrogen) within the last six months.
Other illness
- Medical history of chronic conditions such as liver disease, cancer, or autoimmune diseases.
- Active chronic infections, including HIV, HCV, HBV, and tuberculosis.
- History of renal allograft failure within the past year.
Other
- Current pregnancy or lactation.
- Refusal to participate in the study.
Who the study is looking for
- Patients of both sexes aged 18 years and older.
- Patients undergoing maintenance hemodialysis three times weekly for at least six months.
- Patients who are not scheduled for kidney transplantation within the next year.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Urology and Nephrology Center, Mansoura University Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.